<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03300466</url>
  </required_header>
  <id_info>
    <org_study_id>43FE1630</org_study_id>
    <nct_id>NCT03300466</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Performance and Safety of GP0045 for Correction of Moderate to Severe Nasolabial Folds</brief_title>
  <official_title>A Randomized, Controlled, Evaluator-blinded, Split Face Study to Evaluate the Performance and Safety of GP0045 for Correction of Moderate to Severe Nasolabial Folds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to assess the performance and safety of GP0045 when injected in the
      nasolabial folds.

      There is an 18 months follow up period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2017</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to evaluate the response rate based on the Wrinkle Severity Rating Scale (WSRS) following injection of GP0045 in the treatment of NLF</measure>
    <time_frame>6 months</time_frame>
    <description>The response rate based on the Wrinkle Severity Rating Scale (WSRS) at 6 months post treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Nasolabial Fold</condition>
  <condition>Safety</condition>
  <arm_group>
    <arm_group_label>GP0045</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with GP0045</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with active comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GP0045</intervention_name>
    <description>Hyaluronic acid gel</description>
    <arm_group_label>GP0045</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Comparator</intervention_name>
    <description>Hyaluronic acid gel</description>
    <arm_group_label>Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to adequately understand the verbal explanations and the written subject
             information provided in local language and ability to give consent to participate in
             the study

          -  Signed and dated informed consent to participate in the study, including photo consent

          -  Subjects with intent to undergo correction of both nasolabial folds

        Exclusion Criteria:

          -  Known/previous allergy or hypersensitivity to any injectable HA gel

          -  Known/previous allergy or hypersensitivity to local anesthetics, e.g. lidocaine or
             other amide-type anesthetics

          -  Any condition (medical or other) that, in the opinion of the Investigator, would make
             the subject unsuitable for inclusion (e.g. a chronic, relapsing or hereditary disease
             that may interfere with the outcome of the study)

          -  Participation in any other clinical study with an investigational product within 30
             days before treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CTC AB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Q-Med AB</last_name>
    <phone>+46184749000</phone>
    <email>q-med@galderma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Q-Med</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Q-Med AB</last_name>
      <phone>+46184749000</phone>
      <email>q-med@galderma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2017</study_first_submitted>
  <study_first_submitted_qc>September 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2017</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyaluronic Acid, Lidocaine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

